Spinal Cord Stimulator Trial Lead Migration

Jaymin Patel, MD; Ryan Mattie, MD; Vivek Babaria, DO; and Zachary L. McCormick, MD on behalf of the Spine Intervention Society’s Patient Safety Committee

1Emory University, Department of Orthopaedics, Atlanta, Georgia, USA; 2Providence Cedars-Sinai Tarzana Medical Center, Department of Interventional Pain & Spine, Los Angeles, California, USA; 3Orange County Spine and Sports, PC, Interventional Physiatry, Costa Mesa, California, USA; 4University of Utah, Division of Physical Medicine and Rehabilitation, Salt Lake City, Utah, USA

Myth: The use of proper anchoring techniques will successfully mitigate safety concerns related to lead migration during spinal cord stimulation (SCS) trials.

Fact: Sutting percutaneous SCS leads does not mitigate the risk of migration compared to taping alone during a trial. Most lead migration does not pose a safety concern during the trial period.

Spinal cord stimulation (SCS), is FDA-approved for the treatment of failed back surgery syndrome, complex regional pain syndrome and painful neuropathy, among other conditions. Typically, a trial (temporary or permanent) is performed, and implantation is considered if the patient reports at least 50% relief of their index pain [1]. SCS lead migration has been reported to range from 13-22% [2, 3]. Techniques to limit SCS lead migration, particularly during implantation, have improved over the years but this complication remains a primary reason for explant [4, 5]. Data describing trial SCS lead migration is more scarce, with a rates as low as 0.7% [3] but up to 23% [6]. Investigators have sought to identify risk factors for SCS lead migration during trials in order to identify precautionary measures.

Risk Factors for Spinal Cord Stimulation Lead Migration

Understanding the risks for SCS lead migration provides insight in identifying those patients who may be most susceptible to the occurrence. Unfortunately, there is a paucity of evidence addressing such risk factors, particularly for SCS trials. Kumar et al. reported that lead migration, including both percutaneous and paddle leads, after implantation occurred more often in the cervical than thoracic spine [7]. It was suggested that this finding might be related to the greater degree of mobility in the cervical compared to thoracic spine. A different study evaluated reasons for readmission within 30 days of SCS lead implantation and identified lead migration and infection as the two most common causes [8]. Only one medical comorbidity (obesity) was an independent predictor of readmission (OR 1.86 [CI 1.18, 2.95]; p value 0.008), however, it was not associated with any specific readmission diagnosis (i.e. lead migration). These studies only provide circumstantial evidence that the level of lead placement and patient co-morbidities, specifically obesity, may be related to lead migration. There is no evidence available regarding the level of epidural entry and its effect on lead migration during SCS trials.

Spinal Cord Stimulation Trial Lead Anchoring Techniques

Osborne et al. investigated whether suturing through a silastic anchor and taping versus taping alone limited SCS lead migration during a three-day trial [9]. In both groups, the leads were taped in a “fan-like manner” and looped caudal to the entry point on the skin. The taping technique involved applying an adhesive to the skin and wrapping a strip of skin closure tape around the lead with subsequent affixation to the skin with additional tape applied sequentially along the lead. The mean distance of lead migration (caudal) was 24.49mm (SD 11.3) in the suture and tape group compared to 8.72mm (SD 5.77) in the tape only group (p=0.001, 95% CI: 7.3-24.2). As a clinical reference, the average disc height of T8-9 has been reported to be 5.3 mm and with T8 vertebral body height of 18.5 mm [10]. The increased migration in the suture and tape group was felt to be due to increased tension on the lead resulting in an “inch worm” effect with flexion-based activities.
Efforts have also been made to investigate the ability of intrinsic anatomical structures as anchors that may be capable of limiting SCS lead migration. Mironer et al. retrospectively compared patients who underwent a “traditional trial” with ipsilateral (unilateral pain) or midline (bilateral pain) single-lead placement versus a group that underwent “midline anchoring” technique which theoretically engages the plica mediana dorsalis to stabilize the lead[6]. The plica median dorsalis is a band of connective tissue between the ligamentum flavum and dura. This was performed by introducing the lead from the contralateral side to the patient’s symptoms. A significant difference in migration rate, 23% (11-48%) in the ipsilateral approach compared to 6% (2-15%) in the contralateral approach, was noted. Notably, there were no complications associated with the observed migrations. Unfortunately, lead migration itself was not confirmed by imaging to quantify the migration or assess the plane of migration (vertical or transverse) and based solely on symptom coverage. An acknowledged limitation in applying the contralateral technique is the variable morphology of the plica mediana dorsalis [11]. Transverse migration is not well studied in SCS trials. Long-term experiences with SCS implants reveals that the majority of migration occurs in a cephalocaudad (vertical) dimension [7].

**Positional Changes That Influence Migration**

Many physicians advise patients to avoid bending, lifting or twisting during the SCS trial period in order to prevent lead migration. Kim et al. assessed SCS lead migration associated with positional changes at the end of a 7-day trial period in a total of 24 patients [12]. Leads were sutured and secured via wound closure strips to the skin. At the end of the seven-day trial period, patients with sufficient pain relief to proceed with implantation were divided into two groups representing those who experienced a change in paresthesia during the trial and those who did not. Imaging was performed with the patients in sitting and standing positions. There was an average caudal lead migration of 2.85 mm (95% CI: 2.3-3.4) in the group that noted paresthesia change during the trial. In patients who did not experience a change in paresthesias, there was a mean lead migration in the caudal direction of 3.24 mm (95% CI: 2.69 -3.79). These data suggest that there was no significant difference in lead migration when comparing those patients who experienced a change in paresthesia to those who did not.

**Complications Related to Spinal Cord Stimulation Lead Migration**

There is a case report of cephalad lead migration to the C2 level from a thoracic SCS lead placement [11]. The patient noted right upper extremity pain during a five-day trial after reporting that the original bandage had lost adherence and a new one was applied at home. The SCS leads were removed in clinic without complication and antibiotics were started to account for the possibility of skin flora introduction into the epidural space. Another case involved a patient being treated for failed back surgery syndrome with sutured trial leads placed at T8 and T9 who described chest pain and chest wall paresthesia on the second day of the trial [13]. A cardiac work-up was negative and the imaging revealed that one of the leads had migrated to the T1 level. The leads were eventually removed without further complication. These cases confirm that the leads can migrate great distances and cause new symptoms or result in loss of pain coverage.

**Summary**

1. Lead migration during SCS trial does not appear to result in long-term patient sequelae, but may cause new pain, impact treatment efficacy or require a repeat or revision procedure.
2. Lead suturing does not eliminate lead migration and there is evidence that it could paradoxically increase lead migration compared to taping alone. The effectiveness of specific anchoring techniques remains speculative.
3. It is reasonable to advise patients to follow post-procedure restrictions during the trial period including avoiding any bending or twisting, and to abstain from manipulation of the procedure site.
4. Counsel the patient on potential symptoms of lead migration including decreased pain relief, new pain, paresthesias in locations not observed initially, and any neurologic changes. This should prompt x-ray imaging to assess the location of trial leads.
5. Although cephalad lead migration has been observed, caudal migration is more common.
6. It is advisable to perform an x-ray to confirm the level of the electrodes at the end of the SCS trial in order to determine if lead migration occurred during the trial period if the decision to proceed with implantation is made.
References